INBP — Integrated Biopharma Balance Sheet
0.000.00%
Last trade - 00:00- $8.79m
- $6.33m
- $50.32m
- 100
- 99
- 52
- 97
Annual balance sheet for Integrated Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.402 | 0.21 | 0.331 | 1.32 | 1.68 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5.51 | 5.78 | 4.89 | 4.51 | 4.67 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 16.5 | 18 | 16.6 | 16.4 | 17.9 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.52 | 4.11 | 3.78 | 4.28 | 3.67 |
| Other Long Term Assets | |||||
| Total Assets | 22.9 | 25.4 | 25.3 | 25.4 | 26.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 13.1 | 9.24 | 5.26 | 4.83 | 6.12 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 16.9 | 11.1 | 6.67 | 6.57 | 6.97 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 6.07 | 14.3 | 18.6 | 18.9 | 19.2 |
| Total Liabilities & Shareholders' Equity | 22.9 | 25.4 | 25.3 | 25.4 | 26.2 |
| Total Common Shares Outstanding |